Fiduciary Management Inc. WI Decreases Stock Position in Henry Schein, Inc. $HSIC

Fiduciary Management Inc. WI cut its stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 6.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,293,597 shares of the company's stock after selling 146,742 shares during the period. Henry Schein comprises about 1.9% of Fiduciary Management Inc. WI's holdings, making the stock its 18th largest holding. Fiduciary Management Inc. WI owned about 1.95% of Henry Schein worth $173,350,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HSIC. Assenagon Asset Management S.A. raised its position in shares of Henry Schein by 212.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 67,181 shares of the company's stock worth $5,078,000 after acquiring an additional 45,701 shares in the last quarter. Kettle Hill Capital Management LLC acquired a new stake in shares of Henry Schein during the 3rd quarter worth about $14,158,000. Tudor Investment Corp ET AL acquired a new stake in shares of Henry Schein during the 3rd quarter worth about $15,375,000. Snyder Capital Management L P raised its position in shares of Henry Schein by 18.6% during the 3rd quarter. Snyder Capital Management L P now owns 1,334,364 shares of the company's stock worth $88,562,000 after acquiring an additional 209,123 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Henry Schein by 171.9% during the 4th quarter. SG Americas Securities LLC now owns 820,698 shares of the company's stock worth $62,028,000 after acquiring an additional 518,914 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on HSIC. Citigroup began coverage on Henry Schein in a research report on Wednesday, April 15th. They set a "buy" rating and a $100.00 target price on the stock. Wells Fargo & Company raised their target price on Henry Schein from $76.00 to $87.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 25th. Mizuho cut their target price on Henry Schein from $88.00 to $82.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 6th. UBS Group reissued a "neutral" rating and set a $85.00 target price (down from $87.00) on shares of Henry Schein in a research report on Wednesday, May 6th. Finally, Barrington Research set a $97.00 target price on Henry Schein and gave the stock an "outperform" rating in a research report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Henry Schein presently has a consensus rating of "Hold" and a consensus target price of $86.83.

Insider Activity at Henry Schein

In related news, Director William K. Daniel purchased 10,000 shares of the company's stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average price of $69.19 per share, for a total transaction of $691,900.00. Following the transaction, the director directly owned 20,000 shares of the company's stock, valued at approximately $1,383,800. The trade was a 100.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Thomas C. Popeck sold 1,355 shares of the business's stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $72.79, for a total value of $98,630.45. Following the completion of the transaction, the chief executive officer owned 86,182 shares in the company, valued at $6,273,187.78. This trade represents a 1.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.89% of the stock is currently owned by insiders.

Henry Schein Stock Up 1.5%

Henry Schein stock opened at $77.45 on Friday. Henry Schein, Inc. has a fifty-two week low of $61.94 and a fifty-two week high of $89.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. The company has a market capitalization of $8.82 billion, a P/E ratio of 23.40, a PEG ratio of 1.49 and a beta of 0.82. The stock has a 50-day simple moving average of $74.70 and a 200-day simple moving average of $75.93.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The business had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. During the same period in the previous year, the business earned $1.15 EPS. The business's quarterly revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities research analysts expect that Henry Schein, Inc. will post 5.32 earnings per share for the current year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.